Achieve Life Sciences, Inc. (NASDAQ: ACHV) completed a private placement that will bring in up to $354 million in gross proceeds. The transaction, closed on April 17, 2026, provides $180 million in upfront cash and up to an additional $174 million in milestone‑driven warrants that become exercisable within 20 days of FDA approval of cytisinicline for smoking cessation.
The deal issued 49,418,069 shares of common stock at $3.635 per share, or an equivalent number of pre‑funded warrants at $3.634 per warrant. In addition, the investors received warrants to purchase up to 49,518,569 shares at an exercise price of $3.51 per share, with expiration tied to the later of the FDA approval announcement or the company’s notification of approval. The lead investors include Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace.
The capital raise is intended to fund the Phase 3 clinical trial of cytisinicline in vaping cessation, support commercialization activities, and provide working capital. Prior to the financing, Achieve’s cash balance stood at $36.4 million as of December 31, 2025, with annual operating expenses of $54.9 million, implying a runway of roughly six to eight months. The infusion therefore extends the company’s ability to pursue regulatory approval and launch the product in the first half of 2027.
Andrew D. Goldberg, MD, has been appointed chief executive officer, effective after closing. In a statement, Dr. Goldberg said, "Cytisinicline represents a generational public health opportunity to combat both smoking—the leading cause of preventable death—and the rapid rise of vaping, which is putting a new generation at risk." Former CEO Rick Stewart noted, "The completion of the analytical transfer and the first batch now in the manufacturing site firmly positions Achieve to meet the goal of manufacturing cytisinicline drug product in the U.S." Thomas King, chairman of the board, added, "His clinical experience as a practicing physician, combined with his proven track record in healthcare investment and commercial strategy, make him ideally suited to drive operational excellence, financial execution and shareholder value for Achieve."
Manufacturing and regulatory headwinds remain. On April 15, 2026, the company’s contract manufacturer received an Official Action Indicated classification from the FDA due to general cGMP matters, raising the likelihood of a Complete Response Letter. The company expects to resubmit its New Drug Application in Q4 2026, with a potential launch in the first half of 2027. These risks temper the optimism surrounding the financing, underscoring the importance of the capital raise in maintaining the company’s development trajectory.
The announcement was met with positive market sentiment, driven by the substantial capital infusion and the appointment of a new CEO with a strong clinical and investment background. Investors viewed the financing as a critical step in extending the company’s cash runway and advancing cytisinicline toward regulatory approval and market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.